|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
RP Warrell , BJ Lee, SJ Kempin, MJ Lacher, DJ Straus and CW Young
We treated 51 patients with advanced malignant lymphoma refractory to
conventional therapy with methyl-glyoxal-bis(guanylhydrazone) (methyl- GAG)
at doses ranging from 400 to 800 mg/sq m. Therapy was started on a weekly
schedule and was switched to every other week in responding patients at the
onset of toxicity. Partial responses were observed in 6 of 13 evaluable
patients with Hodgkin's disease (46%), 5 of 10 patients with diffuse poorly
differentiated lymphocytic lymphoma (50%), 2 of 4 patients with nodular
poorly differentiated lymphocytic lymphoma (50%), and 3 of 13 patients with
diffuse histiocytic lymphoma (23%). Two of six patients with mycosis
fungoides showed objective improvement in cutaneous disease. Toxicity was
generally mild and included muscular weakness, myalgia, mucositis, and
diarrhea; two patients developed bronchospasm following drug infusions. We
conclude that methyl-GAG has major antitumor activity when administered on
this schedule to patients with advanced malignant lymphoma. The low degree
of toxicity, unique mechanism of action, and minimal myelosuppressive
effects suggest that methyl-GAG will prove useful in future trials of
combination chemotherapy regimens for the treatment of lymphoma.
This article has been cited by other articles:
| |||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 1981 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
